Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy [Phase 3]
Phase 3 randomized trial comparing two dosing schedules for hypofractionated image-guided radiation therapy in melanoma and ovarian cancer. …
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) [Phase 1]
Phase 1 study evaluating APX005M in combination with nivolumab and ipilimumab in treatment-naïve patients with advanced melanoma or renal ce…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma [NA]
Ongoing clinical trial evaluating whether Beta Glucan influences the immunologic response to pembrolizumab in patients with stage III or sta…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma [Phase 1, Phase 2]
Update on safety results from a combination therapy using an adenovirus vector engineered to express hIL-12 with an Activator Ligand in mela…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors [Phase 2]
A Phase 2 trial evaluating niraparib in patients with advanced PALB2-mutated tumors was terminated; results have been posted for multiple so…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) [Phase 1, Phase 2]
Phase 1/2 substudy evaluating pembrolizumab alone or with investigational agents in melanoma brain metastases has completed. The update high…
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) [Phase 1, Phase 2]
This update covers a Phase 1/2 trial of pembrolizumab, alone or with investigational agents, in Stage III melanoma patients eligible for neo…
-
CLINICAL_TRIALS research · 2025-10-27Clinical Trial Update: Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
The clinical trial update reports that the study on spontaneous regression in metastatic melanoma and renal cell carcinoma remains active bu…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors [Phase 1, Phase 2]
Results from a Phase 1/2 study of E7386 in combination with pembrolizumab in previously treated solid tumors (melanoma, hepatocellular carci…
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy [Phase 1]
A Phase 1 trial evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy for patients with advanced cancers; the st…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients [Phase 3]
A Phase 3 study evaluating a melanoma vaccine in stage IIb, IIc, and III melanoma has been terminated, with results posted.
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) [NA]
The EDEN trial investigates how diet and exercise may affect immunotherapy outcomes and the gut microbiome in melanoma patients; the study s…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: Taxoprexin® Treatment for Advanced Eye Melanoma [Phase 2]
Phase 2 trial update reports completion of Taxoprexin studies for advanced eye melanoma; the excerpt does not include efficacy or safety res…
-
EMA withdrawal · 2025-10-23EMA Application withdrawn: Amtagvi (lifileucel) — Iovance Biotherapeutics B.V.
EMA has withdrawn the application for Amtagvi (lifileucel) for melanoma.
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors [Phase 1]
The Phase 1 trial of HFB301001 in adults with advanced solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: High-Risk Skin Cancers With Atezolizumab Plus NT-I7 [Phase 1, Phase 2]
A terminated Phase 1/2 trial evaluating the combination of atezolizumab and NT-I7 for high-risk skin cancers (melanoma, Merkel cell carcinom…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma [Phase 2]
Phase 2 neoadjuvant trial comparing dostarlimab alone vs cobolimab plus dostarlimab in melanoma is currently active but not recruiting. The …
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors [Phase 1]
This Phase 1 trial update reports on the combination of MGC018 and MGD019 in participants with advanced solid tumors, including castration-r…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: YASU Research Registry: For Young Adults With Cancer
Clinical trial update indicating termination of the YASU Research Registry for young adults with cancer, listing several cancer conditions i…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of radiation therapy with a DLL3-targeting bispecific T-cell engager in DLL3-expres…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer [NA]
This clinical trial update describes the IM@HOME Integrative Medicine at Home program for cancer patients and indicates that recruitment is …
-
CLINICAL_TRIALS research · 2025-10-08Clinical Trial Update: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of intratumoral MVR-T3011 given alone or with pembrolizumab in adults with advanced o…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors [Phase 2]
Phase 2 clinical trial evaluating atezolizumab in combination with BDB001 and immunogenic radiotherapy for advanced solid tumors is currentl…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors [Phase 2]
This Phase 2 clinical trial investigates several radiation dose levels for patients whose cancers progressed on immunotherapy/checkpoint inh…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies [Phase 1, Phase 2]
Incyte reports a completed phase 1/2 trial evaluating a three-drug immunotherapy combo (INCMGA00012 anti-PD-1, INCAGN02385 anti-LAG-3, INCAG…